Schillinger, Wolfgang

[["dc.bibliographiccitation.firstpage","286"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","EuroIntervention"],["dc.bibliographiccitation.lastpage","293"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Korte, Kerstin Pia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Danner, Bernhard"],["dc.contributor.author","Schoendube, Friedrich"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.date.accessioned","2021-06-01T10:48:55Z"],["dc.date.available","2021-06-01T10:48:55Z"],["dc.date.issued","2017"],["dc.description.abstract","AIMS: The objective of this study was to examine the impact of guideline-defined subtypes of severe aortic stenosis (AS) on long-term outcomes after TAVI. METHODS AND RESULTS: Four hundred (400) consecutive patients who underwent TAVI (203 transapical, 197 transfemoral) at our institution 8/2008-3/2013 were followed systematically (for up to seven years). One hundred and forty-seven (147) individuals suffered from NEF-HG AS (LV-EF ≥50%, high Pmean ≥40 mmHg), 63 from LEF-HG AS (LV-EF <50%, high gradient), 77 from PLF-LG AS (LV-EF ≥50%, low gradient, stroke volume index [SVI] <35 ml/m²), and 81 from LEF-LG AS (LV-EF <50%, low gradient). LEF-LG status was associated with the highest all-cause and cardiovascular mortality and MACCE rate, whereas NEF-HG patients exhibited the best outcome (i.e., median survival 5.1 years in NEF-HG vs. 1.3 years in LEF-LG, p=0.0006; or vs. 3.3 years in PLF-LG, p=0.02). In multivariate analysis, LEF-LG status emerged as the outcome predictor with the highest hazard ratio for all-cause mortality (HR 2.86, p=0.003), cardiovascular mortality (HR 6.53, p<0.0001), and MACCE (HR 2.44, p=0.007), whereas neither baseline EF nor SVI <35 ml/m² independently predicted these endpoints. CONCLUSIONS: These findings suggest that an assessment of LV-EF alone for outcome prediction after TAVI is inadequate; it is the guideline-defined subtype of AS that determines outcome."],["dc.identifier.doi","10.4244/EIJ-D-16-00801"],["dc.identifier.gro","3142338"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86102"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","final"],["dc.relation.issn","1774-024X"],["dc.title","Long-term outcomes after TAVI in patients with different types of aortic stenosis: the conundrum of low flow, low gradient and low ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","225"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Circulation Research"],["dc.bibliographiccitation.lastpage","227"],["dc.bibliographiccitation.volume","95"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.date.accessioned","2017-09-07T11:43:19Z"],["dc.date.available","2017-09-07T11:43:19Z"],["dc.date.issued","2004"],["dc.identifier.doi","10.1161/01.RES.0000139434.26969.4f"],["dc.identifier.gro","3143958"],["dc.identifier.isi","000223116000001"],["dc.identifier.pmid","15297383"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1529"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0009-7330"],["dc.title","Is modulation of sodium-calcium exchange a therapeutic option in heart failure?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1202"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","1210"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Iliadis, Christos"],["dc.contributor.author","Baldus, Stephan"],["dc.contributor.author","Kalbacher, Daniel"],["dc.contributor.author","Boekstegers, Peter"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Ouarrak, Taoufik"],["dc.contributor.author","Zahn, Ralf"],["dc.contributor.author","Butter, Christian"],["dc.contributor.author","Zuern, Christine S."],["dc.contributor.author","Bardeleben, Ralph Stephan"],["dc.contributor.author","Senges, Jochen"],["dc.contributor.author","Bekeredjian, Raffi"],["dc.contributor.author","Eggebrecht, Holger"],["dc.contributor.author","Pfister, Roman"],["dc.date.accessioned","2020-12-10T14:06:20Z"],["dc.date.available","2020-12-10T14:06:20Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1002/ejhf.1820"],["dc.identifier.eissn","1879-0844"],["dc.identifier.issn","1388-9842"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69856"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Impact of left atrial diameter on outcome in patients undergoing edge‐to‐edge mitral valve repair: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","673"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","680"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Teucher, Nils"],["dc.contributor.author","Christians, Claus"],["dc.contributor.author","Kohlhaas, Michael"],["dc.contributor.author","Sossalla, Samuel"],["dc.contributor.author","Van Nguyen, Phuc"],["dc.contributor.author","Schmidt, Albrecht G."],["dc.contributor.author","Schunck, Ortwin"],["dc.contributor.author","Nebendahl, Klaus"],["dc.contributor.author","Maier, Lars S."],["dc.contributor.author","Zeitz, Oliver"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.date.accessioned","2017-09-07T11:52:27Z"],["dc.date.available","2017-09-07T11:52:27Z"],["dc.date.issued","2006"],["dc.description.abstract","We investigated the hypothesis that increased intracellular [Na+](i) in heart failure contributes to preservation of SR Ca2+ load which may become particularly evident at slow heart rates. [Na+]i in SBFI-loaded myocytes from rabbits with pacing-induced heart failure (PHF) was significantly higher at each frequency as compared to Sham-operated animals. Furthermore, PHF rabbits demonstrated reduced SR Ca2+-ATPase protein levels (-37%, p < 0.04) but unchanged Na+/Ca2+ exchanger protein levels. At 0.25 Hz, isometric force was similar in cardiac trabeculae from PHF rabbits as compared to control (PHF, 3.6 +/- 1.3; Sham, 4.4 +/- 0.6 mN/mm(2)). Rapid cooling contractures (RCCs) were unchanged indicating preserved SR Ca2+ load at this frequency. In Sham, isometric twitch force increased with rising frequencies to 29.0 +/- 2.8 mN/mm(2) at 3.0 Hz (p < 0.05) as compared to 0.25 Hz. RCCs showed a parallel increase by 186 +/- 47% (p < 0.01). In PHF, frequency-dependent increase in force (15.8 +/- 4.7 mN/mm(2) at 3.0 Hz) and RCCs (increase by 70 +/- 40%) were significantly blunted. Thus, in PHF in rabbits SR Ca2+ load is preserved at low frequencies despite decreased SR Ca2+-ATPase expression. This may result from [Na+](i)-dependent changes in Na+/Ca2+ exchanger activity. (c) 2006 European Society of Cardiology. Published by Elsevier B.V All rights reserved."],["dc.identifier.doi","10.1016/j.ejheart.2006.01.013"],["dc.identifier.gro","3143598"],["dc.identifier.isi","000242383300002"],["dc.identifier.pmid","16540370"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1130"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1388-9842"],["dc.title","High intracellular Na+ preserves myocardial function at low heart rates in isolated myocardium from failing hearts"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","996"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Cardiovascular Research"],["dc.bibliographiccitation.lastpage","1003"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Ohler, A."],["dc.contributor.author","Embry, S. L."],["dc.contributor.author","Muller, F"],["dc.contributor.author","Christians, Claus"],["dc.contributor.author","Janssen, P. M. L."],["dc.contributor.author","Kogler, H."],["dc.contributor.author","Teucher, Niels"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Seidler, Tim"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.date.accessioned","2021-06-01T10:50:03Z"],["dc.date.available","2021-06-01T10:50:03Z"],["dc.date.issued","2003"],["dc.description.abstract","Objectives: The functional consequences of Na+/Ca2+ exchanger (NCX) overexpression in heart failure have been controversially discussed. NCX function strongly depends on intracellular sodium which has been shown to be increased in heart failure. Methods and results: We investigated the Na+/K+-ATPase (NKA) inhibitor ouabain (0.5-16 mumol/l) in electrically stimulated, isotonically contracting adult rabbit cardiocytes overexpressing NCX after adenoviral gene transfer (Ad-NCX-GFP, 48 h culture time). Myocytes transfected with adenovirus encoding for green fluorescent protein (Ad-GFP) served as a control. Contractions were analyzed by video-edge detection. In the Ad-NCX-GFP group, the maximum inotropic response was significantly reduced by 50.7% (P < 0.05). This was a result of an enhanced susceptibility to contracture after exposure to the drug (median concentration (25-75%): 4 (4-8) vs. 8 (6-16) mumol/l, P < 0.05). When analyzing relaxation before contracture, the maximum relaxation velocity was reduced (0.15 +/- 0.04 vs. 0.27 +/- 0.04 mum/s, P < 0.05) and the time from peak shortening to 90% of relaxation was increased (298 +/- 39 vs. 185 +/- 15 ms, P < 0.05). No differences in systolic and diastolic parameters were observed with the Na+ channel modulator BDF9198 (1 mumol/l). Conclusions: Inhibition of NKA by ouabain induces a combined diastolic and systolic dysfunction in NCX overexpressing rabbit myocytes. This may be the consequence of cytoplasmic Ca2+ overload due to inhibition of forward mode or induction of reverse mode Na+/Ca2+ exchange. In end-stage failing human myocardium and during digitalis treatment this mechanism may be of major importance. (C) 2003 European Society of Cardiology. Published by Elsevier Science B.V. All rights reserved."],["dc.identifier.doi","10.1016/S0008-6363(02)00829-5"],["dc.identifier.gro","3144121"],["dc.identifier.isi","000181975100014"],["dc.identifier.pmid","12650877"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86511"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0008-6363"],["dc.title","The functional effect of adenoviral Na+/Ca2+ exchanger overexpression in rabbit myocytes depends on the activity of the Na+/K+-ATPase"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","27"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.lastpage","28"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Lubos, Edith"],["dc.contributor.author","Boekstegers, Peter"],["dc.contributor.author","von Bardeleben, R. S."],["dc.contributor.author","Butter, Christian"],["dc.contributor.author","Zuern, Christine S."],["dc.contributor.author","Ouarrak, Taoufik"],["dc.contributor.author","Eggebrecht, Holger"],["dc.contributor.author","Senges, Jochen"],["dc.date.accessioned","2018-11-07T09:53:28Z"],["dc.date.available","2018-11-07T09:53:28Z"],["dc.date.issued","2015"],["dc.identifier.isi","000361205101093"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36337"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","Congress of the European-Society-of-Cardiology (ESC)"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1522-9645"],["dc.relation.issn","0195-668X"],["dc.title","One-year outcome after mitraclip implantation - Results from the German TRAMI registry"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","323"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Der Internist"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.date.accessioned","2018-11-07T10:16:25Z"],["dc.date.available","2018-11-07T10:16:25Z"],["dc.date.issued","2016"],["dc.description.abstract","The percutaneous edge-to-edge mitral valve repair with MitraClipA (R) is evolving as a potential alternative to conventional surgery in high-risk patients with significant mitral regurgitation (MR). The randomized controlled EVEREST II-trial which compared percutaneous repair versus surgery in operable patients with symptomatic severe MR demonstrated superior safety of MitraClipA (R) implantation but better MR reduction after surgery at 12 months. However, large registries on MitraClipA (R) therapy showed that real-world MitraClipA (R) patients differ significantly from the EVEREST II-cohort: they are older, in more advanced stages of heart failure, present predominantly with secondary MR, and exhibit a higher burden of comorbidities. For these patients, registry data confirm a low incidence of peri-interventional complications and a significant improvement of heart failure symptoms and quality of life measures after MitraClipA (R) implantation. The ongoing RESHAPE trial with randomization of MitraClipA (R) implantation against optimal medical therapy investigates a possible survival benefit after MitraClipA (R) in patients with secondary MR."],["dc.identifier.doi","10.1007/s00108-016-0033-y"],["dc.identifier.isi","000373226300004"],["dc.identifier.pmid","26968857"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41036"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-1289"],["dc.relation.issn","0020-9554"],["dc.title","Catheter-based mitral valve repair by MitraClip implantation. Development, studies, and use in clinical practice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1488"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","EuroIntervention"],["dc.bibliographiccitation.lastpage","1490"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","van Rosendael, Philippe"],["dc.contributor.author","van der Kley, Frank"],["dc.contributor.author","Martina, Bryan"],["dc.contributor.author","Palmen, Meindert"],["dc.contributor.author","Delgado, Victoria"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","von Bardeleben, Ralph Stephan"],["dc.contributor.author","Yeo, Khung Keong"],["dc.contributor.author","Ho, Kay Woon"],["dc.contributor.author","Tan, Wei Chieh Jack"],["dc.date.accessioned","2018-11-07T09:58:47Z"],["dc.date.available","2018-11-07T09:58:47Z"],["dc.date.issued","2015"],["dc.description.abstract","BACKGROUND: A 74-year-old male with symptomatic severe recurrent mitral regurgitation after surgical mitral valve repair and high surgical risk was referred for transcatheter mitral valve-in-ring implantation. INVESTIGATION: Two- and three-dimensional transoesophageal echocardiography, fluoroscopy. DIAGNOSIS: After transapical deployment of a 26 mm SAPIEN XT (Edwards Lifesciences, Irvine, CA, USA) in a mitral ring (Physio II ring, size 30; Edwards Lifesciences) and removal of the guidewire, severe para-ring mitral regurgitation originating at the level of the posterior commissure was detected. MANAGEMENT: A 6 mm AMPLATZER (TM) septal occluder system (St. Jude Medical, St. Paul, MN, USA) was implanted at the level of the para-ring dehiscence with significant reduction in para-ring mitral regurgitation. Transthoracic echocardiography pre-discharge showed a mean transmitral gradient of 7 mmHg and minimal mitral regurgitation."],["dc.identifier.doi","10.4244/EIJY14M09_02"],["dc.identifier.isi","000356844000020"],["dc.identifier.pmid","25244565"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37439"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Europa Edition"],["dc.relation.issn","1969-6213"],["dc.relation.issn","1774-024X"],["dc.title","How should I treat recurrent concomitant para-ring and valvular mitral regurgitation after surgical mitral valve repair in a high-risk patient?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","981"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.lastpage","982"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Zahn, Ralph"],["dc.contributor.author","Bauer, T."],["dc.contributor.author","Baldus, S."],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Franzen, Olaf"],["dc.contributor.author","Bekeredijan, R."],["dc.contributor.author","Sievert, Horst"],["dc.contributor.author","Schofer, Joachim"],["dc.contributor.author","Kuck, Karl-Heinz"],["dc.contributor.author","Senges, Jochen"],["dc.date.accessioned","2018-11-07T09:21:36Z"],["dc.date.available","2018-11-07T09:21:36Z"],["dc.date.issued","2013"],["dc.identifier.isi","000327744606121"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29145"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","Congress of the European-Society-of-Cardiology (ESC)"],["dc.relation.eventlocation","Amsterdam, NETHERLANDS"],["dc.relation.issn","1522-9645"],["dc.relation.issn","0195-668X"],["dc.title","The role of gender during percutaneous catheter-based treatment of mitral insufficiency with the MitraClip TM system"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","335"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","340"],["dc.bibliographiccitation.volume","207"],["dc.contributor.author","Kefer, Joelle"],["dc.contributor.author","Tzikas, Apostolos"],["dc.contributor.author","Freixa, Xavier"],["dc.contributor.author","Shakir, Samera"],["dc.contributor.author","Gafoor, Sameer"],["dc.contributor.author","Nielsen-Kudsk, Jens Erik"],["dc.contributor.author","Berti, Sergio"],["dc.contributor.author","Santoro, Gennaro"],["dc.contributor.author","Aminian, Adel"],["dc.contributor.author","Landmesser, Ulf"],["dc.contributor.author","Nietlispach, Fabian"],["dc.contributor.author","Ibrahim, Reda"],["dc.contributor.author","Danna, Paolo Luciano"],["dc.contributor.author","Benit, Edouard"],["dc.contributor.author","Budts, Werner"],["dc.contributor.author","Stammen, Francis"],["dc.contributor.author","De Potter, Tom"],["dc.contributor.author","Tichelbaecker, Tobias"],["dc.contributor.author","Gloekler, Steffen"],["dc.contributor.author","Kanagaratnam, Prapa"],["dc.contributor.author","Costa, Marco"],["dc.contributor.author","Cruz-Gonzalez, Ignacio"],["dc.contributor.author","Sievert, Horst"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Park, Jai-Wun"],["dc.contributor.author","Meier, Bernhard"],["dc.contributor.author","Omran, Heyder"],["dc.date.accessioned","2018-11-07T10:16:50Z"],["dc.date.available","2018-11-07T10:16:50Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Left atrial appendage occlusion (LAAO) using the Amplatzer cardiac plug (ACP) is a preventive treatment of atrial fibrillation related thromboembolism. Aim: To assess the safety and efficacy of LAAO in patients with chronic kidney disease (CKD). Methods: Among the ACP multicentre registry, 1014 patients (75 +/- 8 yrs) with available renal function were included. Results: Patients with CKD (N = 375, CHA2DS2-VASc: 4.9 +/- 1.5, HASBLED: 3.4 +/- 1.3) were at higher risk than patients without CKD (N = 639, CHA2DS2-VASc: 4.2 +/- 1.6, HASBLED: 2.9 +/- 1.2; p < 0.001 for both). Procedural (97%) and occlusion (99%) success were similarly high in all stages of CKD. Peri-procedural major adverse events (MAE) were observed in 5.1% of patients, 0.8% of death, with no difference between patients with and those without CKD (6.1 vs 4.5%, p = 0.47). In patients with complete follow-up (1319 patients years), the annual stroke + transient ischaemic attack (TIA) rate was 2.3% and the observed bleeding rate was 2.1% (62 and 60% less than expected, similarly among patients with and those without CKD). Kaplan-Meier analysis showed a lower overall survival (84 vs 96% and 84 vs 93% at 1 and 2 yrs. respectively; p < 0.001) among patients with an eGFR <30 ml/min/1.73 m(2). Conclusion: LAAO using the ACP has a similar procedural safety among CKD patients compared to patients with normal renal function. LAAO with ACP offers a dramatic reduction of stroke + TIA rate and of bleeding rate persistent in all stages of CKD, as compared to the expected annual risk. (C) 2016 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2016.01.003"],["dc.identifier.isi","000371271400099"],["dc.identifier.pmid","26820363"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41114"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]